Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus R-CHOP for primary mediastinal B-cell lymphoma
ACTRN12621001529831Phase 2Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Event-free survival. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on ACTRN12621001529831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001529831.